<DOC>
	<DOCNO>NCT01109511</DOCNO>
	<brief_summary>Objectives : Primary objective : - To demonstrate treatment OXN PR tablets 72 hr surgery superior treatment OxyPR regard constipation subject postoperative pain laparoscopic hysterectomy base interview 24h , 72 h 1 week postoperatively . The secondary objective : - Analgesic effect ( include registration first 24 hr ) - To asses frequency pain rescue mediation use ( double-blind phase , 0-72 hr ) - Frequency nausea vomit - Frequency adverse event - Appetite - Mobilization The exploratory objective : - Overall patient satisfaction 24 , 72 hr 1 week</brief_summary>
	<brief_title>A Comparison Oxycodone/Naloxone Oxycodone After Laparoscopic Hysterectomy</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>1 . Females 18 70 year 2 . Elective , nonmalignant laparoscopic gynecological surgery general anesthesia : hysterectomy/ myomectomy , ASA 1 , 2 3 3 . Subjects willing able participate study provide informed consent form 1 . Previous recent regular opioid use ( WHO step I pain treatment allow ) 2 . Any situation opioids contraindicate . 3 . Any history moderate severe hepatic impairment . 4 . Any history severe respiratory depression hypoxia and/or hypercapnia 5 . Any history severe chronic obstructive pulmonary disease , cor pulmonal , acute severe bronchial asthma 6 . Subjects evidence nonopioid induce paralytic ileus 7 . Subjects evidence severely impaired pulmonary function , myxoedema , hypothyroidism 8 . Subjects evidence Addison 's disease ( adrenal cortical insufficiency ) , toxic psychosis , cholelithiasis , prostate hypertrophy , alcoholism , delirium , pancreatitis , hypotension , hypertension , preexist cardiovascular disease , head injury ( due risk increase intracranial pressure ) , epileptic disorder predisposition convulsion , patient take MAO inhibitor . 9 . Any history hypersensitivity Oxycodone / Naloxone excipients . 10 . Active alcohol drug abuse and/or history opioid abuse . 11 . Subjects evidence clinically unstable disease , determine medical history , clinical laboratory test , ECG result , physical examination , Investigator 's opinion , preclude entry study . 12 . Subjects receive investigational medicinal product within 30 day study entry ( defined start Screening Period ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>